<sup>18</sup>F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use.
Where this comes from
- Record sourced from PubMed, PMID 37169533.
- Also identified by DOI 10.2967/jnumed.123.265622.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecular imaging of the somatostatin receptor plays a key role in the clinical management of neuroendocrine tumors. PET imaging with somatostatin analogs (SSAs) labeled with <sup>68</sup>Ga or <sup>64</sup>Cu is currently the gold standard in clinical practice. However, widespread implementation of <sup>68</sup>Ga imaging is often hampered by practical and economic issues related to <sup>68</sup>Ge/<sup>68</sup>Ga generators. <sup>18</sup>F offers several advantages to tackle these issues. Recent developments in radiochemistry have allowed a shift from <sup>68</sup>Ga toward <sup>18</sup>F labeling, leading to promising clinical translations of <sup>18</sup>F-labeled SSAs, such as Gluc-Lys-[<sup>18</sup>F]FP-TOCA, [<sup>18</sup>F]F-FET-βAG-TOCA, [<sup>18</sup>F]AlF-NOTA-octreotide, [<sup>18</sup>F]SiTATE, and [<sup>18</sup>F]AlF-NOTA-JR11. This review gives an update of currently available clinical data regarding <sup>18</sup>F-labeled SSA tracers and provides justification for the clinical application of this class of tracers.
Medical subject headings
- Somatostatin
- Neuroendocrine Tumors